Hüseyin Saygin Tuna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hüseyin Saygin Tuna has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Reichardt
Department of Interventional Radiology and Neuroradiology, Hochsauerland Hospital, Arnsberg, Germany
2 shared publications - Fahrettin Kucukay
Department of Radiology, Eskisehir Osmangazi University, Faculty of Medicine, Eskisehir, Turkey
2 shared publications - Fahrettin Kucukay
Department of Interventional Radiology, Faculty of Medicine, Eskisehir Osmangazi University, Buyukdere Meselik Yerleskesi, Odunpazari, Eskisehir, Turkey
2 shared publications Patrick Haage
HELIOS University Hospital Wuppertal: HELIOS Universitatsklinikum Wuppertal
2 shared publications- Patrick Haage
Department of Radiology, HELIOS University Hospital Wuppertal, University Witten/Herdecke, Wuppertal, Germany
2 shared publications - Afonso Quelhas Fonseca
Interventional Radiology Unit, Curry Cabral Hospital, Unidade Local de Saúde São José; Centro Clínico Académico de Lisboa, Lisbon, Portugal
1 shared publication
Latest Publications
- Open Access
Selective Arterial Embolization for Renal Angiomyolipoma: A Giant Versus Non-Giant Lesion Subgroup Comparison
Selective arterial embolization (SAE) is an established nephron-sparing option for renal angiomyolipoma (AML), but it remains unclear whether giant lesions (≥10 cm) respond less well or carry higher procedural risk. We retrospectively reviewed 40 patients treated with SAE between 2020 and 2025. Tris-acryl gelatin microspheres (300–500 µm) were the primary embolic agent; N-butyl cyanoacrylate or microcoils were added in 12 patients with acute bleeding or large aneurysms. Pre- and post-procedural values were compared with the Wilcoxon signed-rank test, and giant and non-giant lesions with the Mann–Whitney U and Fisher’s exact tests. Thirty-six patients (90%) were women, and 14 (35%) had giant lesions. Technical success reached 100% and clinical success 97.5% (39/40); no major complications occurred. Mean tumor diameter decreased by 13.6% (83.6 ± 47.2 vs. 72.7 ± 41.8 mm; p < 0.001), while estimated glomerular filtration rate (eGFR) did not change significantly (94.6 ± 21.6 vs. 87.7 ± 33.1 mL/min/1.73 m2; p = 0.203). Giant and non-giant lesions did not differ significantly in clinical success (92.9% vs. 100%; p > 0.999), shrinkage, or renal function (all p > 0.05). One patient with a giant, multifocal, tuberous sclerosis complex-associated lesion did not respond and underwent nephrectomy. These data suggest that tumor size alone may not preclude SAE.
Open AccessSelective Arterial Embolization for Renal Angiomyolipoma: A Giant Versus Non-Giant Lesion Subgroup Comparison
Selective arterial embolization (SAE) is an established nephron-sparing option for renal angiomyolipoma (AML), but it remains unclear whether giant lesions (≥10 cm) respond less well or carry higher procedural risk. We retrospectively reviewed 40 patients treated with SAE between 2020 and 2025. Tris-acryl gelatin microspheres (300–500 µm) were the primary embolic agent; N-butyl cyanoacrylate or microcoils were added in 12 patients with acute bleeding or large aneurysms. Pre- and post-procedural values were compared with the Wilcoxon signed-rank test, and giant and non-giant lesions with the Mann–Whitney U and Fisher’s exact tests. Thirty-six patients (90%) were women, and 14 (35%) had giant lesions. Technical success reached 100% and clinical success 97.5% (39/40); no major complications occurred. Mean tumor diameter decreased by 13.6% (83.6 ± 47.2 vs. 72.7 ± 41.8 mm; p < 0.001), while estimated glomerular filtration rate (eGFR) did not change significantly (94.6 ± 21.6 vs. 87.7 ± 33.1 mL/min/1.73 m2; p = 0.203). Giant and non-giant lesions did not differ significantly in clinical success (92.9% vs. 100%; p > 0.999), shrinkage, or renal function (all p > 0.05). One patient with a giant, multifocal, tuberous sclerosis complex-associated lesion did not respond and underwent nephrectomy. These data suggest that tumor size alone may not preclude SAE.
- Open Access
- 15 October 2026
- Published by Springer Nature in CardioVascular and Interventional Radiology
- p. 1-17
Balloon-Occlusion Versus End-Hole Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Purpose: To evaluate the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) compared with conventional (cTACE) and drug-eluting-bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma. Materials and Methods: A systematic review and meta-analysis was conducted following PRISMA guidelines and registered in PROSPERO. PubMed, Scopus, and the Cochrane Central Register of Controlled Trials were searched to 8 February 2026 for randomized and observational studies comparing B-TACE with cTACE or DEB-TACE. Tumor response (mRECIST), overall survival, and adverse events were pooled using random-effects models; risk of bias was assessed with established tools. Results: Nine studies (one randomized, eight observational; 1534 patients) were included. Complete response, objective response, disease control, and progressive disease did not differ significantly between groups, with moderate-to-substantial heterogeneity. Baseline tumors were larger in the balloon-occluded group (mean difference 4.34 mm; 95% CI 1.18- 7.50; p = 0.014). Exploratory study-level analyses suggested greater relative B-TACE effects with larger tumors, particularly for complete response and disease control.Overall survival favored B-TACE in the two studies with extractable hazard ratios (HR 0.41; 95% CI 0.23 to 0.73; p = 0.002). Post-treatment liver enzymes, bilirubin, fever, and post-embolization syndrome did not differ significantly. Conclusion: No statistically significant differences in imaging response or safety were observed between intervention and comparator groups, while B-TACE was associated with a signal toward improved overall survival despite larger baseline tumors. Exploratory findings suggested that larger tumor size may be associated with a greater relative B-TACE effect. Given the limited evidence, these findings require confirmation in randomized controlled trials.
- 15 October 2026
- Published by Springer Nature in CardioVascular and Interventional Radiology
- p. 1-17
Open AccessBalloon-Occlusion Versus End-Hole Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Purpose: To evaluate the efficacy and safety of balloon-occluded transarterial chemoembolization (B-TACE) compared with conventional (cTACE) and drug-eluting-bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma. Materials and Methods: A systematic review and meta-analysis was conducted following PRISMA guidelines and registered in PROSPERO. PubMed, Scopus, and the Cochrane Central Register of Controlled Trials were searched to 8 February 2026 for randomized and observational studies comparing B-TACE with cTACE or DEB-TACE. Tumor response (mRECIST), overall survival, and adverse events were pooled using random-effects models; risk of bias was assessed with established tools. Results: Nine studies (one randomized, eight observational; 1534 patients) were included. Complete response, objective response, disease control, and progressive disease did not differ significantly between groups, with moderate-to-substantial heterogeneity. Baseline tumors were larger in the balloon-occluded group (mean difference 4.34 mm; 95% CI 1.18- 7.50; p = 0.014). Exploratory study-level analyses suggested greater relative B-TACE effects with larger tumors, particularly for complete response and disease control.Overall survival favored B-TACE in the two studies with extractable hazard ratios (HR 0.41; 95% CI 0.23 to 0.73; p = 0.002). Post-treatment liver enzymes, bilirubin, fever, and post-embolization syndrome did not differ significantly. Conclusion: No statistically significant differences in imaging response or safety were observed between intervention and comparator groups, while B-TACE was associated with a signal toward improved overall survival despite larger baseline tumors. Exploratory findings suggested that larger tumor size may be associated with a greater relative B-TACE effect. Given the limited evidence, these findings require confirmation in randomized controlled trials.
- Open Access
- 12 August 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1) , 97
Genicular artery embolization for refractory pain after knee arthroplasty: clinical outcomes from a retrospective pilot study
Background: Refractory pain after knee arthroplasty without prosthetic loosening, infection, or mechanical failure remains a therapeutic challenge for which few non-surgical options are available. Genicular artery embolization (GAE) has shown promise in knee osteoarthritis, but evidence in patients treated after arthroplasty remains limited. The aim of this study was to evaluate the technical feasibility, safety, and short- to mid-term clinical outcomes of GAE using imipenem/cilastatin (IPM/CLS) in this population. Results: Fifteen consecutive patients (9 men, 6 women; median age, 67 years) underwent GAE between January 2022 and December 2025 for refractory pain after total knee, unicompartmental, or isolated retropatellar arthroplasty. Hypervascular periarticular branches were embolized with an IPM/CLS suspension through common femoral arterial access. Outcomes were assessed using the Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Total Analgesic Consumption Score (TACS) at baseline and 1, 3, 6, and 12 months. Technical success was 100%. Median NRS fell from 7.0 (interquartile range, 6.0–8.0) at baseline to 1.0 at 1 month ( p < 0.001), 3.0 at 3 and 6 months, and 5.0 at 12 months ( p = 0.018). Median WOMAC decreased from 32.0 to 20.0 ( p = 0.032) and KOOS from 20.0 to 14.0 ( p = 0.041) at 12 months. TACS improved significantly through 6 months ( p ≤ 0.026); 4 of 7 patients on baseline opioids had discontinued by 12 months. At 12 months, 5 of 9 evaluable patients (56%) maintained a ≥ 2-point NRS reduction and 4 of 9 (44%) achieved a ≥ 30% reduction. Repeat embolization was performed in 3 patients (20%). No major complications occurred; minor transient adverse events occurred in 2 patients (13%): mild periarticular discomfort and self-limited skin erythema. Conclusions: In this small retrospective pilot cohort, GAE using IPM/CLS appeared technically feasible and safe and was associated with early pain reduction. Sustained clinically meaningful benefit at 12 months was limited to a subset of patients, indicating variable durability. These findings should be interpreted with caution and require confirmation in larger prospective studies.
- 12 August 2026
- Published by Springer Nature in CVIR Endovascular
- Vol. 9 (1) , 97
Open AccessGenicular artery embolization for refractory pain after knee arthroplasty: clinical outcomes from a retrospective pilot study
Background: Refractory pain after knee arthroplasty without prosthetic loosening, infection, or mechanical failure remains a therapeutic challenge for which few non-surgical options are available. Genicular artery embolization (GAE) has shown promise in knee osteoarthritis, but evidence in patients treated after arthroplasty remains limited. The aim of this study was to evaluate the technical feasibility, safety, and short- to mid-term clinical outcomes of GAE using imipenem/cilastatin (IPM/CLS) in this population. Results: Fifteen consecutive patients (9 men, 6 women; median age, 67 years) underwent GAE between January 2022 and December 2025 for refractory pain after total knee, unicompartmental, or isolated retropatellar arthroplasty. Hypervascular periarticular branches were embolized with an IPM/CLS suspension through common femoral arterial access. Outcomes were assessed using the Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Total Analgesic Consumption Score (TACS) at baseline and 1, 3, 6, and 12 months. Technical success was 100%. Median NRS fell from 7.0 (interquartile range, 6.0–8.0) at baseline to 1.0 at 1 month ( p < 0.001), 3.0 at 3 and 6 months, and 5.0 at 12 months ( p = 0.018). Median WOMAC decreased from 32.0 to 20.0 ( p = 0.032) and KOOS from 20.0 to 14.0 ( p = 0.041) at 12 months. TACS improved significantly through 6 months ( p ≤ 0.026); 4 of 7 patients on baseline opioids had discontinued by 12 months. At 12 months, 5 of 9 evaluable patients (56%) maintained a ≥ 2-point NRS reduction and 4 of 9 (44%) achieved a ≥ 30% reduction. Repeat embolization was performed in 3 patients (20%). No major complications occurred; minor transient adverse events occurred in 2 patients (13%): mild periarticular discomfort and self-limited skin erythema. Conclusions: In this small retrospective pilot cohort, GAE using IPM/CLS appeared technically feasible and safe and was associated with early pain reduction. Sustained clinically meaningful benefit at 12 months was limited to a subset of patients, indicating variable durability. These findings should be interpreted with caution and require confirmation in larger prospective studies.
- Open Access
- 25 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2334
Imipenem/Cilastatin Sodium as Reabsorbable Embolic Agent in Acute Lower Gastrointestinal Bleeding: A Multicentric Prospective Study
Background/Objectives: This study aims to analyze safety and effectiveness of imipenem/cilastatin sodium (IPM/CS) as an off-label embolic agent in acute lower gastrointestinal bleeding (LGIB). Methods: This is a multicentric prospective study including patients treated in emergency with endovascular embolization for acute LGIB. IPM/CS particles were prepared using one vial containing 500 mg/500 mg of IPM/CS in powder diluted with 5 mL of pure iodine contrast agent. Inclusion criteria were: acute bleeding managed with IMP/CS embolization, unfeasible/ineffective endoscopic management, availability of a pre-procedural contrast-enhanced Computed Tomography (CT) scan, pre- and post-procedural blood count, pre- and post-procedural hemodynamic balance evaluation, and follow-up to 30 days. Exclusion criteria were: patients treated in elective conditions, LGIB embolization performed without IMP/CS, IMP/CS adoption after other embolics, incomplete clinical–laboratoristic follow-up, and age < 18 years. Technical success was intended as angiographic disappearance of extravasation or significant reduction/stasis of blood flow to the target; clinical success was considered as hemoglobin values increase and/or stop transfusions and/or hemodynamic restoration. Result: Twenty-one patients were enrolled; bleeding etiologies included angiodysplasia, diverticular disease, gastrointestinal tumor-related bleeding, and post-surgical hemorrhage. Technical success rate was 100%, and clinical success rate at 30 days was 85.7%. Rebleeding occurred in three patients: two managed with surgery and one with coil re-embolization. Neither major and IPM/CS related complications occurred. Conclusions: In this study IPM/CS was a safe and feasible embolic agent in selected patients with acute LGIB; no bowel ischemia occurred during the 30 day follow-up. Future studies with larger samples are required to confirm these findings to include IPM/CS as an off-label alternative embolic agent in LGIB.
- 25 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2334
Open AccessImipenem/Cilastatin Sodium as Reabsorbable Embolic Agent in Acute Lower Gastrointestinal Bleeding: A Multicentric Prospective Study
Background/Objectives: This study aims to analyze safety and effectiveness of imipenem/cilastatin sodium (IPM/CS) as an off-label embolic agent in acute lower gastrointestinal bleeding (LGIB). Methods: This is a multicentric prospective study including patients treated in emergency with endovascular embolization for acute LGIB. IPM/CS particles were prepared using one vial containing 500 mg/500 mg of IPM/CS in powder diluted with 5 mL of pure iodine contrast agent. Inclusion criteria were: acute bleeding managed with IMP/CS embolization, unfeasible/ineffective endoscopic management, availability of a pre-procedural contrast-enhanced Computed Tomography (CT) scan, pre- and post-procedural blood count, pre- and post-procedural hemodynamic balance evaluation, and follow-up to 30 days. Exclusion criteria were: patients treated in elective conditions, LGIB embolization performed without IMP/CS, IMP/CS adoption after other embolics, incomplete clinical–laboratoristic follow-up, and age < 18 years. Technical success was intended as angiographic disappearance of extravasation or significant reduction/stasis of blood flow to the target; clinical success was considered as hemoglobin values increase and/or stop transfusions and/or hemodynamic restoration. Result: Twenty-one patients were enrolled; bleeding etiologies included angiodysplasia, diverticular disease, gastrointestinal tumor-related bleeding, and post-surgical hemorrhage. Technical success rate was 100%, and clinical success rate at 30 days was 85.7%. Rebleeding occurred in three patients: two managed with surgery and one with coil re-embolization. Neither major and IPM/CS related complications occurred. Conclusions: In this study IPM/CS was a safe and feasible embolic agent in selected patients with acute LGIB; no bowel ischemia occurred during the 30 day follow-up. Future studies with larger samples are required to confirm these findings to include IPM/CS as an off-label alternative embolic agent in LGIB.
- Open Access
- 16 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (14) , 2217
Transarterial Microembolization in Refractory Plantar Fasciitis: Functional and Patient-Reported Early- to Midterm Outcomes from a Single-Center Pilot Study
Background/Objectives: Chronic plantar fasciitis refractory to conservative treatment remains a therapeutic challenge, and minimally invasive options targeting pathologic neovascularization are of growing interest. We evaluated the safety and early- to midterm clinical outcomes of transarterial microembolization in refractory plantar fasciitis, with emphasis on functional and patient-reported outcomes. Methods: In this single-center observational pilot study with ambispective data collection, 16 procedures in 13 patients were treated using imipenem/cilastatin. The primary outcome was pain intensity (Numeric Rating Scale, NRS); secondary outcomes included the Foot Function Index (FFI), the Patient Global Impression of Change (PGIC), analgesic use, return to activity, need for further treatment, and complications. Results: Technical success was 100%. Median NRS decreased from 10.0 at baseline to 3.0 at 1 month and 0.0 at 3 months, with significant improvement maintained through 18 months. Median FFI improved from 9.42 to near zero, and analgesic use declined. At 12 months, 90.9% of procedures reported clinical improvement. Reintervention was required once (6.3%); only minor complications occurred (12.5%), with no major events. Full return to normal activity was achieved in 68.8%. Conclusions: Transarterial microembolization was associated with rapid functional and patient-reported improvement and a favorable safety profile. These exploratory, hypothesis-generating findings warrant confirmation in controlled prospective studies.
- 16 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (14) , 2217
Open AccessTransarterial Microembolization in Refractory Plantar Fasciitis: Functional and Patient-Reported Early- to Midterm Outcomes from a Single-Center Pilot Study
Background/Objectives: Chronic plantar fasciitis refractory to conservative treatment remains a therapeutic challenge, and minimally invasive options targeting pathologic neovascularization are of growing interest. We evaluated the safety and early- to midterm clinical outcomes of transarterial microembolization in refractory plantar fasciitis, with emphasis on functional and patient-reported outcomes. Methods: In this single-center observational pilot study with ambispective data collection, 16 procedures in 13 patients were treated using imipenem/cilastatin. The primary outcome was pain intensity (Numeric Rating Scale, NRS); secondary outcomes included the Foot Function Index (FFI), the Patient Global Impression of Change (PGIC), analgesic use, return to activity, need for further treatment, and complications. Results: Technical success was 100%. Median NRS decreased from 10.0 at baseline to 3.0 at 1 month and 0.0 at 3 months, with significant improvement maintained through 18 months. Median FFI improved from 9.42 to near zero, and analgesic use declined. At 12 months, 90.9% of procedures reported clinical improvement. Reintervention was required once (6.3%); only minor complications occurred (12.5%), with no major events. Full return to normal activity was achieved in 68.8%. Conclusions: Transarterial microembolization was associated with rapid functional and patient-reported improvement and a favorable safety profile. These exploratory, hypothesis-generating findings warrant confirmation in controlled prospective studies.
- 9 July 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (10) , 108949
Endovascular Embolization of Left-Sided Varicocele: Outcomes by Venographic Anatomy and Coil-Adjunct Strategy
- 9 July 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (10) , 108949
Endovascular Embolization of Left-Sided Varicocele: Outcomes by Venographic Anatomy and Coil-Adjunct Strategy
- 30 May 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (9) , 108873
Thyroid Artery Embolization for Benign Symptomatic Multinodular Euthyroid Goiter: 24-Month Outcomes from a Single-Center Retrospective Study
- 30 May 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (9) , 108873
Thyroid Artery Embolization for Benign Symptomatic Multinodular Euthyroid Goiter: 24-Month Outcomes from a Single-Center Retrospective Study
- Open Access
- 25 March 2026
- Published by Springer Nature in Research Square
Genicular Artery Embolization for Refractory Pain After Total Knee Arthroplasty: Clinical Outcomes From a Pilot Study
Purpose : To evaluate the clinical outcomes and safety of selective transarterial genicular artery embolization (GAE) in patients with refractory pain following knee arthroplasty without evidence of prosthetic loosening, infection, or mechanical failure. Materials and Methods: This single-center retrospective cohort study included consecutive patients who underwent GAE for refractory post-arthroplasty knee pain between January 2022 and December 2025. Pain and functional outcomes were assessed using the Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS) and Total Analgesic Consumption Score (TACS) at baseline and at 1, 3, 6, and 12 months. Changes from baseline were analyzed using the paired Wilcoxon signed-rank test. Complications were classified according to Society of Interventional Radiology standards. Results : Fifteen patients (median age, 67 years) underwent GAE. Median baseline NRS was 7.0 (IQR, 6.0–8.0). Significant pain reduction was observed at 1 month (median NRS, 1.0; p < 0.001) and pain reduction was most pronounced during the first 6 months, with partial attenuation at 12 months. WOMAC and KOOS scores demonstrated parallel significant improvements through 12 months (p ≤ 0.041). TACS scores improved significantly through 6 months (p ≤ 0.026). Repeat embolization was performed in 3 patients (20%). No major complications occurred; minor transient adverse events were observed in 2 patients (13%). Conclusion : Genicular artery embolization was associated with significant improvements in pain and function with a favorable safety profile in patients with refractory post-arthroplasty knee pain.
- 25 March 2026
- Published by Springer Nature in Research Square
Open AccessGenicular Artery Embolization for Refractory Pain After Total Knee Arthroplasty: Clinical Outcomes From a Pilot Study
Purpose : To evaluate the clinical outcomes and safety of selective transarterial genicular artery embolization (GAE) in patients with refractory pain following knee arthroplasty without evidence of prosthetic loosening, infection, or mechanical failure. Materials and Methods: This single-center retrospective cohort study included consecutive patients who underwent GAE for refractory post-arthroplasty knee pain between January 2022 and December 2025. Pain and functional outcomes were assessed using the Numeric Rating Scale (NRS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Knee Injury and Osteoarthritis Outcome Score (KOOS) and Total Analgesic Consumption Score (TACS) at baseline and at 1, 3, 6, and 12 months. Changes from baseline were analyzed using the paired Wilcoxon signed-rank test. Complications were classified according to Society of Interventional Radiology standards. Results : Fifteen patients (median age, 67 years) underwent GAE. Median baseline NRS was 7.0 (IQR, 6.0–8.0). Significant pain reduction was observed at 1 month (median NRS, 1.0; p < 0.001) and pain reduction was most pronounced during the first 6 months, with partial attenuation at 12 months. WOMAC and KOOS scores demonstrated parallel significant improvements through 12 months (p ≤ 0.041). TACS scores improved significantly through 6 months (p ≤ 0.026). Repeat embolization was performed in 3 patients (20%). No major complications occurred; minor transient adverse events were observed in 2 patients (13%). Conclusion : Genicular artery embolization was associated with significant improvements in pain and function with a favorable safety profile in patients with refractory post-arthroplasty knee pain.
- 24 October 2025
- Published by Springer Nature
- p. 3-15
Pre- and Postinterventional Imaging